Trial drug to help prevent relapse in AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 and have AML that is new or “secondary” (not the special APL type called M3).
- Your leukemia is currently in remission (complete remission, CR, or CR with partial blood count recovery, CRh).
- You finished standard initial treatment and then consolidation or a hypomethylating medicine plus venetoclax, within certain cycle limits.
- You can start treatment within 3 months after your most recent documented remission.
- You cannot get an allogeneic (donor) stem cell transplant for any reason.
- Your heart, liver, and kidney tests are within limits, and you’re well enough day-to-day (ECOG 0–3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
This trial tests a combination of cancer medicines for people with acute myeloid leukemia (AML) that is still detectable after initial treatment. It may help by trying to drive leukemia into a deeper remission when it lingers at low levels.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Hear when a new Acute Myeloid Leukemia (AML) in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.